Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Reata Pharma (RETA)

Reata Pharma (RETA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Reata Pharmaceuticals, Inc. (RETA) Down 37.8% Since Last Earnings Report: Can It Rebound?

Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

RETA : 149.99 (+0.73%)
WPD PHARMACEUTICALS ANNOUNCES BRAIN CANCER PATIENT FROM BERUBICIN PHASE 1 TRIAL REMAINS CANCER FREE

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the "Company" or "WPD") a clinical stage pharmaceutical company, is pleased to announce that a patient from the Phase 1 clinical trial of its Berubicin...

RETA : 149.99 (+0.73%)
WBIO.CN : 0.740 (-2.63%)
WPD PHARMACEUTICALS ANNOUNCES BRAIN CANCER PATIENT FROM BERUBICIN PHASE 1 TRIAL REMAINS CANCER FREE

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the "Company" or "WPD") a clinical stage pharmaceutical company, is pleased to announce that a patient from the Phase 1 clinical trial of its Berubicin...

RETA : 149.99 (+0.73%)
WBIO.CN : 0.740 (-2.63%)
Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2019 Financials and Provides an Update on Development Programs

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) ("Reata," the "Company," or "we"), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and full year ended December...

RETA : 149.99 (+0.73%)
Reata Pharmaceuticals, Inc. to Report Fourth Quarter and Full Year 2019 Financials and to Provide an Update on Development Programs on February 19, 2020

Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on recent progress on its development...

RETA : 149.99 (+0.73%)
CNS Pharmaceuticals Announces Completion of GMP Manufacturing

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biotechnology company specializing in the development of novel treatments for brain tumors, today announced it has completed the final...

RETA : 149.99 (+0.73%)
CNSP : 2.12 (-11.30%)
CNS Pharmaceuticals Filed Request with FDA for Pre-IND Meeting for Berubicin

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("Company"), a biotechnology company specializing in the development of novel treatments for brain tumors, filed a Pre-IND meeting request for Berubicin for IV...

RETA : 149.99 (+0.73%)
CNSP : 2.12 (-11.30%)
Reata Pharmaceuticals, Inc. Announces Closing of Class A Common Stock Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) ("Reata" or the "Company"), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of...

RETA : 149.99 (+0.73%)
Reata Pharmaceuticals, Inc. Announces Pricing of Upsized Class A Common Stock Public Offering

Reata Pharmaceuticals, Inc. (Nasdaq:RETA) ("Reata" or the "Company"), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 2,400,000 shares of its...

RETA : 149.99 (+0.73%)
Reata Pharmaceuticals, Inc. Announces Proposed Public Offering of Class A Common Stock

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) ("Reata" or the "Company"), a clinical-stage biopharmaceutical company, today announced its intention to offer and sell 2,000,000 shares of its Class A common...

RETA : 149.99 (+0.73%)
Reata Pharmaceuticals, Inc. (RETA) Reports Q3 Loss, Tops Revenue Estimates

Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of -5.60% and 5.17%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the...

RETA : 149.99 (+0.73%)
Reata Pharmaceuticals, Inc. Announces Third Quarter 2019 Financial Results and an Update on Development Programs

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) ("Reata" or the "Company"), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2019, and...

RETA : 149.99 (+0.73%)
Reata Pharmaceuticals, Inc. to Report Third Quarter 2019 Financial Results and to Provide an Update on Development Programs on November 12, 2019

Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on recent progress on its development...

RETA : 149.99 (+0.73%)
Reata (RETA) Jumps: Stock Rises 5. 6%

Reata (RETA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

AVEO : 4.28 (-0.47%)
RETA : 149.99 (+0.73%)
Reata Successfully Completes Neuromuscular Disorder Study

Reata (RETA) rallies following the successful completion of a pivotal study evaluating omaveloxolone as a potential treatment for Friedreich's ataxia, a progressive neuromuscular disorder.

ABBV : 72.67 (-1.57%)
FCSC : 3.00 (unch)
RETA : 149.99 (+0.73%)
BGNE : 125.52 (-0.61%)
Reata Pharmaceuticals, Inc. Announces Presentations at the American Society for Nephrology Kidney Week 2019

Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that three abstracts highlighting clinical and nonclinical data for bardoxolone methyl (bardoxolone)...

RETA : 149.99 (+0.73%)
Reata Pharmaceuticals Reacquires Rights From AbbVie to Develop and Commercialize Bardoxolone Methyl, Omaveloxolone, and All Next-Generation Nrf2 Activators

Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced the reacquisition of development, manufacturing and commercialization rights concerning its proprietary...

ABBV : 72.67 (-1.57%)
RETA : 149.99 (+0.73%)
Noteworthy Tuesday Option Activity: RETA, KNX, GT

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Reata Pharmaceuticals Inc , where a total volume of 1,093 contracts has been traded...

RETA : 149.99 (+0.73%)
Is the Options Market Predicting a Spike in Reata Pharmaceuticals (RETA) Stock?

Investors need to pay close attention to Reata Pharmaceuticals (RETA) stock based on the movements in the options market lately.

RETA : 149.99 (+0.73%)
Reata Appoints Manmeet S. Soni as Chief Financial Officer; Jason D. Wilson to Assume New Role as EVP, Operations

Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced the appointment of Manmeet S. Soni as Chief Financial Officer (CFO) and Executive Vice President,...

RETA : 149.99 (+0.73%)

Van Meerten Stock Picks

My 5 Favorite Mid Caps
Summary 100% technical buy signals with current momentum.
CRUS -3.71 , SEDG -8.08 , THC -1.42 , TER -2.66 , LITE -1.30
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar